1 of 5 11/6/2014 3:08 PM

Size: px
Start display at page:

Download "1 of 5 11/6/2014 3:08 PM"

Transcription

1 1 of 5 11/6/2014 3:08 PM : Thursday, November 6, :07:42 PM : NU SF: Basic Information 1. * Title of study: Biomedical Research Study 2. * Short title: Biomedical Study 3. * Brief description: This is a brief description of the biomedical study. 4. * Which selection best describes your study? Biomedical 5. * Principal investigator: Debra Tice 6. * Does the Principal Investigator have any significant financial interests related to this research? 7. * Will an external IRB act as the IRB of record for this study? 8. * Attach the protocol: (include the investigator protocol and full sponsor protocol) Category PI Tice Supplement to Sponsor Protocol(11/10 IRB Protocol Biomedical Sponsored Protocol(11/10 IRB Protocol Protocol templates can be found at the following link: : NU SF: Sources of Funding and Other Support (not integrated with Grants) 1. * Identify each organization supporting this research, financially or otherwise: Funding/Support Sponsor's Grants Office s Source Funding ID ID National Institutes of Health R21 HL SP NIH Grant - Sample Biomedical Study

2 2 of 5 11/6/2014 3:08 PM : NU SF: Study Team Members 1. Identify each additional person involved in the design, conduct, or reporting of the research: Name Roles Financial Involved Phone Interest in Lisa Linn Study no yes jhornstein@huronconsultinggroup.com (312) Team Member 2. Identify each additional external person involved in the design, conduct, or reporting of the research: Name Institution Roles Financial Involved Phone Training Interest in John Doe University Co-Investigator no no johndoe@somestate.edu xxx-xxx-xxxx11/6/2014 of Some State : NU SF: Study Scope 1. * Does the study do any of the following: Specify the use of an approved drug or biologic? Use an unapproved drug or biologic? Use a food or dietary supplement to diagnose, cure, treat, or mitigate a disease or condition? Yes No 2. * Does the study do any of the following: Evaluate the safety or effectiveness of a device? Use a humanitarian use device (HUD)? Yes : NU SF: Drugs No 1. * List all drugs, biologics, foods, and dietary supplements to be used in the study: Drug Name Investigational Drug Code Name Name Drug XXX XXXXX Investigator Drug X 2. * Will the study be conducted under any IND numbers? 3. If so, identify each IND: IND Number IND Holder Other Holder Industry Sponsor John Doe Attach files: (such as IND or other information that was not attached for a specific drug) Category

3 3 of 5 11/6/2014 3:08 PM Investigator Brochure Drug X.docx(11/10 Drug Communication from the FDA with Drug the IND number - Drug X.docx(11/10 Package insert Drug X.docx(11/10 Drug : NU SF: s 1. * Select each device the study will evaluate for safety or effectiveness, or each device the submission will use as an HUD: Humanitarian Use Name t Communication from the FDA with the IND Number Product Labeling Drug t.docx 2. * exemptions applicable to this study: IDE 3. If applicable, identify each IDE and HDE number: IDE / HDE Number IDE/ HDE Holder Other Holder Industry Sponsor John Doe 4. Attach files: (such as IDE, HDE, or other information that was not attached for a specific device) Category Communication from the FDA or sponsor with the IDE number(11/10 Sponsor Verification Letter T with IDE number(11/10 Instructions T(11/10 Labeling T(11/10 : NU SF: Recruitment Materials 1. forms: (include an HHS-approved sample consent document, if applicable) Category HRP BIOMEDICAL TEMPLATE CONSENT DOCUMENT.docx(11/10 Form templates can be found at the following link: 2. Recruitment materials: (add all material to be seen or heard by subjects, including ads) Category Radio ad.docx(11/10 Recruitment

4 4 of 5 11/6/2014 3:08 PM Category Materials : NU SF: Sites 1. Please specify study site(s): Northwestern University (NU) Chicago If the research will be conducted at International Sites, Schools (Preschools, Primary Schools, and/or Secondary Schools), or any Other locations, please specify these locations below: Site Contact Phone External IRB Review Rely on Northwestern's IRB There are no items to display : NU SF: Supporting s Select Category to Show: Attach supporting files, naming them as you want them to appear in the approval letter: Radiation Dosimetry Form.docx Created Category 11/6/ /6/2014 Other Suggested attachments: Completed checklist of meeting Department of Energy requirements, if applicable Other study-related documents not attached on previous forms : NU Edit 1. * Funding/Support Organization: National Institutes of Health 2. Sponsor's funding ID: (assigned by external sponsor) R21 HL Grants office ID: (assigned internally) SP Attach files: (include any grant applications) Category NIH Grant - Sample Biomedical Study(11/10 Sponsor : Add External Study Team Member

5 5 of 5 11/6/2014 3:08 PM 1. * First Name: John * Last Name: Doe * Institution: University of Some State Address: johndoe@somestate.edu Telephone Number: xxx-xxx-xxxx 2. * Training : 11/6/2014 Training : 3. * Role in research: (check all that apply) Co-Investigator 4. * Is the team member involved in the consent process? 5. * Does the Co-Investigator have any significant financial interests related to this research? (If this Study Team Member is not a Co-Investigator, answer "No" to this question). : NU Edit 1. * IND number: * Who holds the IND? Industry Sponsor 3. * Identify the IND holder: John Doe

The Children s Hospital of Philadelphia Committees for the Protection of Human Subjects Policies and Procedures Determination of IND/IDE Requirement

The Children s Hospital of Philadelphia Committees for the Protection of Human Subjects Policies and Procedures Determination of IND/IDE Requirement Page: 1 of 8 I. PURPOSE II. III. IV. The purpose of this Standard Operating Procedure is to delineate when an investigator must obtain an Investigational New Drug (IND) or Investigational Device Exemption

More information

SUBJECT: INSTITUTIONAL REVIEW BOARD (IRB) - HUMANITARIAN USE DEVICES

SUBJECT: INSTITUTIONAL REVIEW BOARD (IRB) - HUMANITARIAN USE DEVICES This policy applies to the following entity(s): Children s Hospital of Wisconsin Children s Hospital and Health System, Inc. Administrative Policy and Procedure Children s Research Institute SUBJECT: INSTITUTIONAL

More information

H-20 Page 1 of 5. Institutional Review Board Policy Manual HUMANITARIAN USE DEVICE (HUD) REQUIREMENTS

H-20 Page 1 of 5. Institutional Review Board Policy Manual HUMANITARIAN USE DEVICE (HUD) REQUIREMENTS H-20 Page 1 of 5 Institutional Review Board Policy Manual HUMANITARIAN USE DEVICE (HUD) REQUIREMENTS PURPOSE: To describe the requirements for McLeod Health IRB review of Humanitarian Use Devices (HUD).

More information

Human Research Protection Program. Investigator Manual

Human Research Protection Program. Investigator Manual Human Research Protection Program Revised July 7, 2014 HRP-910 7/7/2014 2 of 10 Table of Contents What is the purpose of this manual?... 3 What is Human Research?... 3 What is the Human Research Protection

More information

Expanded Access (including Emergency Use & Humanitarian Use Devices)

Expanded Access (including Emergency Use & Humanitarian Use Devices) Expanded Access (including Emergency Use & Humanitarian Use Devices) Bertha delanda, CIP IRB Training Specialist Research Compliance Office March 2012 What Is Expanded Access? Permits use of an investigational

More information

Office for Human Subject Protection. University of Rochester

Office for Human Subject Protection. University of Rochester POLICY 1. Purpose Outline the responsibilities and regulatory requirements when conducting human subject research that involves the use of drugs, agents, biological products, or nutritional products (e.g.,

More information

REGULATORY ISSUES: HOW TO APPLY FOR AN IND. Penny Jester and Maaike Everts

REGULATORY ISSUES: HOW TO APPLY FOR AN IND. Penny Jester and Maaike Everts REGULATORY ISSUES: HOW TO APPLY FOR AN IND Penny Jester and Maaike Everts Outline 2 What is the purpose of an IND? What types of INDs are there? When do you need one? How do you apply for one? How do you

More information

Quality Assurance for the Research Team: Connecting Day-to-Day Operations to a Regulatory Framework

Quality Assurance for the Research Team: Connecting Day-to-Day Operations to a Regulatory Framework 1 Quality Assurance for the Research Team: Connecting Day-to-Day Operations to a Regulatory Framework Mandy Morneault Research Compliance Monitor University of Washington Institute of Translational Health

More information

What is an Investigational Drug? 21CFR312.3(b)

What is an Investigational Drug? 21CFR312.3(b) Review of the Investigational Drug and Device Regulations Changes to the RSRB Online Submission System (ROSS) Application for Drugs and Devices Kelley O'Donoghue Donoghue, Director OHSP, MPH, CIP and Tiffany

More information

ClinicalTrials.gov Registration Guide

ClinicalTrials.gov Registration Guide ClinicalTrials.gov Registration Guide The Food and Drug Administration Amendments Act (FDAAA), National Institutes of Health (NIH) and International Committee of Medical Journal Editors (ICMJE) require

More information

Rules of Human Experimentation

Rules of Human Experimentation Rules of Human Experimentation Elaine Larson CUMC IRB Chair Associate Dean for Research, School of Nursing Professor of Epidemiology, Mailman School of Public Health Oversight for Human Research Office

More information

Standard Operating Procedures Guidelines for Good Clinical Practice

Standard Operating Procedures Guidelines for Good Clinical Practice SOP # CRSC-105 Effective Date 10-22-2013 Version # 1 Version Date 7-30-2013 Standard Operating Procedures Guidelines for Good Clinical Practice Purpose: This SOP outlines the steps required to follow FDA

More information

FDA approval of emergency expanded access use may be requested by telephone, facsimile, or other means of electronic communications.

FDA approval of emergency expanded access use may be requested by telephone, facsimile, or other means of electronic communications. Guidelines for the Submission of an Expanded Access IND to Permit Diagnosis, Monitoring or Treatment of an Individual Patient with an Investigational Drug or a REMS-restricted, Approved Drug Guidelines:

More information

Title: Department: Approved by: Director, Human Research Review and Compliance

Title: Department: Approved by: Director, Human Research Review and Compliance Title: Department: Requirements for Investigational New Drug (IND) for Human- Subjects Research Human Research Affairs Policy Type: Partners System-wide Partners System-wide Template Partners HealthCare

More information

Copyright. Jeremiah J. Kelly (2015). All rights reserved. Further dissemination without express written consent strictly prohibited.

Copyright. Jeremiah J. Kelly (2015). All rights reserved. Further dissemination without express written consent strictly prohibited. Statutory Framework for Devices Medical Devices Investigational Use Application IDE (21 CFR 812) Abbreviated IDE Exempt Pre-Market Approval Applications 510(k) Pre-marketing Notification (21 CFR 807(e))

More information

Expanded Access. to Investigational Drugs & Biologics. for Treatment Use

Expanded Access. to Investigational Drugs & Biologics. for Treatment Use SJMHS Research Compliance Office Guidance Document Expanded Access to Investigational Drugs & Biologics for Treatment Use May 2015 1 Expanded Access to Investigational Drugs & Biologics for Treatment Use

More information

FDA Audit Preparation

FDA Audit Preparation Duke University Office of Audit, Risk and Compliance (OARC) FDA Audit Preparation Margaret M. Groves, JD, CRA, CCRP, CHRC Associate Compliance Officer, Research Compliance Assurance (RCA) External audits

More information

Source Documents and Regulatory Binders October 6, 2016

Source Documents and Regulatory Binders October 6, 2016 Source Documents and Regulatory Binders October 6, 2016 Lisa Wilson, Regulatory Lead, Clinical Trials Office and Mark Alger, CRC, Clinical Trials Office Essential Documents AKA: the stuff in the Reg Binder

More information

Guidelines: c. Providing the investigational drug for the requested use will not interfere with the initiation, conduct, or completion of clinical

Guidelines: c. Providing the investigational drug for the requested use will not interfere with the initiation, conduct, or completion of clinical Guidelines for the Submission of an Expanded Access IND to Permit Diagnosis, Monitoring or Treatment of Intermediate-size Patient Populations with an Investigational Drug or a REMS-restricted, Approved

More information

Agenda: Opportunities in Developing Orphan Drug Products. Mukesh Kumar, PhD, RAC

Agenda: Opportunities in Developing Orphan Drug Products. Mukesh Kumar, PhD, RAC This Seminar is Brought to you by Amarex Clinical Research Washington DC metro area A Product Development Services Company From Lab to Market Approval FDA Meetings Global Regulatory Submissions Global

More information

GOOD CLINICAL PRACTICE (GCP) Series Catalog

GOOD CLINICAL PRACTICE (GCP) Series Catalog GOOD CLINICAL PRACTICE (GCP) Series Catalog CITI Program s GCP series consists of three basic courses and three refresher courses. The basic courses include: GCP for Clinical Trials with Investigational

More information

3.1. Overall Principal Investigator (PI), who holds the IND and is the Sponsor.

3.1. Overall Principal Investigator (PI), who holds the IND and is the Sponsor. SOP #: RCO-100 Page: 1 of 11 1. POLICY STATEMENT: An Overall Principal Investigator (PI) who holds an Investigational New Drug Application (IND) and who is the Sponsor of the research has additional responsibilities

More information

Supply of IND Agents to Multi-center trials by Skilled Academic Sites

Supply of IND Agents to Multi-center trials by Skilled Academic Sites Supply of IND Agents to Multi-center trials by Skilled Academic Sites Paula M. Jacobs, Ph.D. Associate Director, Division of Cancer Treatment and Diagnosis, NCI Cancer Imaging Program June 2016 SNMMI San

More information

APPLICATION INSTRUCTIONS INSTITUTIONAL REVIEW BOARD. Revised January 2010 Page 1

APPLICATION INSTRUCTIONS INSTITUTIONAL REVIEW BOARD. Revised January 2010 Page 1 APPLICATION INSTRUCTIONS INSTITUTIONAL REVIEW BOARD Revised January 2010 Page 1 The IRB Proposal Includes: 1. All documents, other than the informed consent form, should be understandable to an informed

More information

SITE SUBMISSION FORM (SINGLE SITE)

SITE SUBMISSION FORM (SINGLE SITE) *We accept study submissions by email, fax or mail. 1. STUDY INFORMATION A. Sponsor: Protocol.: Study Title: B. Study Type: Drug, Biologic or Dietary Supplement (please complete section C., then proceed

More information

\\NAS1\George\Docs\SoCRA\CCRP communications\study guide management

\\NAS1\George\Docs\SoCRA\CCRP communications\study guide management Five Content Areas Percent of Scored Test Items (Range) in Each Area This table shows the percent of scored test questions that are included in each major content area. Five Content Areas Ethical Principles

More information

Outline of Discussion

Outline of Discussion This final rule is intended to better protect human subjects involved in research, while facilitating valuable research and reducing burden, delay, and ambiguity for investigators. These revisions are

More information

Investigator Manual. Human Subjects Protection Program

Investigator Manual. Human Subjects Protection Program Human Subjects Protection Program HRP-103, Revised June 1, 2015 HRP-103 06/01/2015 2 of 33 Table of Contents Scope... 3 What is the purpose of this manual?... 3 What is Human Research?... 3 What is the

More information

Study Start-Up SS STANDARD OPERATING PROCEDURE FOR Investigator Selection

Study Start-Up SS STANDARD OPERATING PROCEDURE FOR Investigator Selection Effective date of version: April 01, 2012 Study Start-Up SS 202.00 STANDARD OPERATING PROCEDURE FOR Investigator Selection Approval: Nancy M. Paris, MS, FACHE President and CEO 08 March 2012 (Signature

More information

Medidée Services SA. Nano-Tera.ch. 05 February 2015 part 8. PMA, 510k, IDE. Pierre-Alain Sommer

Medidée Services SA. Nano-Tera.ch. 05 February 2015 part 8. PMA, 510k, IDE. Pierre-Alain Sommer Nano-Tera.ch 05 February 2015 part 8 PMA, 510k, IDE Pierre-Alain Sommer Pierre-alain.sommer@medidee.com www.medidee.com Nano-Tera 2015 05.02.2015 USA/FDA Pre Market Approval System - PMA, Pre Market Notifcation

More information

INVESTIGATIONAL DEVICE EXEMPTION APPLICATION. IDE Title (if title being used)

INVESTIGATIONAL DEVICE EXEMPTION APPLICATION. IDE Title (if title being used) INVESTIGATIONAL DEVICE EXEMPTION APPLICATION IDE Title (if title being used) Name of Sponsor Investigator, MD X Professor, Department Icahn School of Medicine at Mount Sinai Date of Submission Form version

More information

POLICY AND PROCEDURE MANUAL

POLICY AND PROCEDURE MANUAL POLICY AND PROCEDURE MANUAL PBRC: POLICY NO. 378.00 ORIGIN DATE: 5/25/2016 IMPACTS: CLINICAL RESEARCH LAST REVISED: 1/1/2017 SUBJECT: SOURCE: PURPOSE PENNINGTON BIOMEDICAL CLINICALTRIALS.GOV POLICY INSTITUTIONAL

More information

Applicability of US Regulations to Canadian Research

Applicability of US Regulations to Canadian Research Applicability of US Regulations to Canadian Research Mary Kate Needler Capital District Health Authority Halifax, Nova Scotia, Canada N2 Stakeholder Meeting August 18, 2014 MK s Conventions: 1. US Regulation

More information

FDA Audit Preparation

FDA Audit Preparation Duke University Ethics and Compliance Office FDA Audit Preparation Margaret M. Groves, JD, CRA, CCRP, CHRC Director, CTQA Agenda External audits Best practices to get ready for audits 2 External Audits

More information

Expanded Access and the Individual Patient IND

Expanded Access and the Individual Patient IND Expanded Access and the Individual Patient IND Research Wednesdays April 26, 2017 Erika Segear Johnson, PhD, RAC Associate Director of Regulatory Affairs Office of Regulatory Affairs and Quality Office

More information

FDA Sponsor and Investigator Responsibility Checklist

FDA Sponsor and Investigator Responsibility Checklist FDA Sponsor and Investigator Responsibility Checklist Principal Investigator: Study Name: CPHS #: IND/IDE #: Name of IND/IDE holder: The following checklist is created based on the Sponsor and Investigator

More information

Conducted Under an IND to Support a

Conducted Under an IND to Support a Using Foreign Clinical Trial Data not Conducted Under an IND to Support a US Application PDA Midwest Chapter Meeting March 15, 2018 2013 2017 Regulatory Compliance Associates Inc. All Rights Reserved.

More information

INVESTIGATOR HANDBOOK

INVESTIGATOR HANDBOOK INVESTIGATOR HANDBOOK INVESTIGATOR HANDBOOK Table of Contents MISSION... 3 FIRST TIME SUBMISSION... 3 EDUCATIONAL REQUIREMENTS... 3 PRINCIPAL INVESTIGATOR NEW STUDY SUBMISSIONS... 4 VULNERABLE POPULATIONS...

More information

RECRUITING OF AND ADVERTISING FOR SUBJECTS

RECRUITING OF AND ADVERTISING FOR SUBJECTS 1. POLICY Steering Committee approved 9/19/11 The informed consent process begins when a potential human research subject first learns of a study, which is usually accomplished through recruitment efforts.

More information

UVA Biorepository & Tissue Research Facility (BTRF) Coded-Specimens Guidance

UVA Biorepository & Tissue Research Facility (BTRF) Coded-Specimens Guidance Last Modified 09/15/2015 UVA Biorepository & Tissue Research Facility (BTRF) Coded-Specimens Guidance Setting up a new coded-specimens protocol with the IRB is very easy and will allow you to receive coded

More information

Streamlining IRB Procedures for Expanded Access

Streamlining IRB Procedures for Expanded Access Streamlining IRB Procedures for Expanded Access Marjorie A. Speers, Ph.D. Executive Director, WCG Foundation Richard Klein Director, FDA Patient Liaison Program Office of Health and Constituent Affairs

More information

Source And Regulatory Documentation for DMID Clinical Studies

Source And Regulatory Documentation for DMID Clinical Studies Source And Regulatory Documentation for DMID Clinical Studies Walt Jones RN, MPH Nurse Consultant Clinical Monitoring Coordinator OCRA, DMID, NIAID November, 2007 Source Data Defined All information in

More information

Introduction to Clinical Research

Introduction to Clinical Research Introduction to Clinical Research What is Clinical Research? Clinical research is medical research that involves people like you. People volunteer to participate in carefully conducted investigations that

More information

GLOBAL HEALTH SUPPLY CHAIN QUALITY ASSURANCE

GLOBAL HEALTH SUPPLY CHAIN QUALITY ASSURANCE GLOBAL HEALTH SUPPLY CHAIN QUALITY ASSURANCE Medical Device Product Questionnaire This questionnaire is used to collect information from vendors with regards to medical devices that fall in any of the

More information

Please note that these flowcharts and checklists are from the IRB Researcher Manual.

Please note that these flowcharts and checklists are from the IRB Researcher Manual. Hello Researcher: Please use the following flowcharts and checklists to help you determine when your research may require a review by the Institutional Review Board (IRB). Please note that these flowcharts

More information

Guidance for IRBs, Clinical Investigators and Sponsors

Guidance for IRBs, Clinical Investigators and Sponsors Guidance for IRBs, Clinical Investigators and Sponsors IRB Responsibilities for Reviewing the Qualifications of Investigators, Adequacy of Research Sites, and the Determination of Whether an IND/IDE is

More information

Human Research Protection Program Good Clinical Practice Guidance for Investigators Regulatory File Essential Documents

Human Research Protection Program Good Clinical Practice Guidance for Investigators Regulatory File Essential Documents Guidance for s Regulatory File Essential s All principal investigators must maintain a regulatory binder or file system, which contains all study documentation. These records may be reviewed at the time

More information

State of the Clinical Trials Industry

State of the Clinical Trials Industry State of the Clinical Trials Industry A Sourcebook of Charts and Statistics 2009 SM 100 N. Washington St., Ste. 301 Boston, MA 02114 www.centerwatch.com ix xxxv 1 41 L I S T O F F I G U R E S A N D T A

More information

Definitions and Acronyms

Definitions and Acronyms Definitions and Acronyms 510(k) A particular FDA Class For Medical Devices AE Adverse Event CFR Code of Federal Regulations CMS United States Center/College for Medicare and Medicaid Services CRA Clinical

More information

US FDA: CMC Issues for INDs

US FDA: CMC Issues for INDs ISBTC Global Regulatory Summit October 29, 2008 US FDA: CMC Issues for INDs Keith Wonnacott, Ph.D. keith.wonnacott@fda.hhs.gov US Food and Drug Administration Center for Biologics Evaluation and Research

More information

Work Instruction - Research Billing Risk

Work Instruction - Research Billing Risk THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO Work Instruction - Research Billing Risk Velos eresearch Version 9.2 Version: 2.0, 04/03/2015 Revision History Version/Amendment #: Version

More information

Investigator-Initiated INDs

Investigator-Initiated INDs Investigator-Initiated INDs Marjorie Small, RN, CCRC Office of Clinical Research 23 May 2011 PPHS/IRB Research Grand Rounds Outline of Presentation I. What is an IND? II. Code of Federal Regulations III.

More information

Please note that these flowcharts and checklists are from the IRB Researcher Manual.

Please note that these flowcharts and checklists are from the IRB Researcher Manual. Hello Researcher: Please use the following flowcharts and checklists to help you determine when your research may require a review by the Institutional Review Board (IRB). Please note that these flowcharts

More information

CGMP Requirements for Investigational Products

CGMP Requirements for Investigational Products PREP #6 CGMP Requirements for Investigational Products Ji-Eun Kim, RPh, PhD Research Pharmacist Regulatory Affairs Office of Research Compliance December 6, 2016 1 CME Disclosure Statement Northwell Health

More information

Maintaining your Investigational Device Exemption (IDE) with the FDA: Keys for Success. Jenna Stump, MS, CCRP Clinical Research Regulatory Specialist

Maintaining your Investigational Device Exemption (IDE) with the FDA: Keys for Success. Jenna Stump, MS, CCRP Clinical Research Regulatory Specialist Maintaining your Investigational Device Exemption (IDE) with the FDA: Keys for Success Jenna Stump, MS, CCRP Clinical Research Regulatory Specialist Agenda How an investigator should prepare and submit

More information

Compliance Department RESEARCH COMPLIANCE MEMORANDUM

Compliance Department RESEARCH COMPLIANCE MEMORANDUM Compliance Department RESEARCH COMPLIANCE MEMORANDUM To: UCD Health Chairs & Chief Administrator Officers From: Nirali Patel, Compliance Manager Kathy Olson, Research Compliance Analyst Re: Department

More information

About Clinical Trials

About Clinical Trials About Clinical Trials A guide for people with CF and their families INSIDE Who Can Participate in a Clinical Trial? Clinical Research Basics Who Is Involved in Clinical Research? Informed Consent Your

More information

National Institute of Allergy and Infectious Diseases National Institutes of Health Department of Health and Human Services

National Institute of Allergy and Infectious Diseases National Institutes of Health Department of Health and Human Services National Institute of Allergy and Infectious Diseases National Institutes of Health Department of Health and Human Services The Division of Microbiology and Infectious Diseases (DMID), National Institute

More information

Strasser, Jane (strassje)

Strasser, Jane (strassje) Strasser, Jane (strassje) From: Strasser, Jane (strassje) Sent: Tuesday, April 12, 2011 11:35 AM To: UC-COMP-MATTERS@LISTSERV.UC.EDU Subject: [UC-COMP-MATTERS] Compliance Matters--April

More information

10/9/2012. Alicia Joy, IRB. Wednesday October 10, Please be sure to sign in and take copies of each handout.

10/9/2012. Alicia Joy, IRB. Wednesday October 10, Please be sure to sign in and take copies of each handout. Wednesday October 10, 2012 Please be sure to sign in and take copies of each handout. 1 Alicia Joy, IRB 2 FH Office of Research Administration Christina Jackson, BSN, RN, CCRC, CHRC 1 ClinicalTrials.gov

More information

The Intersection of Genomics Research and the IDE Regulation

The Intersection of Genomics Research and the IDE Regulation The Intersection of Genomics Research and the IDE Regulation Katherine Donigan, Ph.D. Personalized Medicine Staff FDA/CDRH/OIR October 19, 2017 1 In Vitro Diagnostic (IVD) Regulation Through the 1976 medical

More information

The Research Services Organization (RSO) of the Academic Health Center

The Research Services Organization (RSO) of the Academic Health Center Annual Report 2005 The Research Services Organization (RSO) of the Academic Health Center A Summary of the Eighth Year of Operations Submitted by: Mark S. Paller, M.D., M.S. Director, Research Services

More information

2018 Common Rule Implementation Checklist

2018 Common Rule Implementation Checklist 2018 Common Rule Implementation Checklist High Priority Action Items The following table outlines certain actions institutions should consider taking ahead of the 2018 Common Rule s effective and general

More information

Participant Materials and Retention Program Guidelines

Participant Materials and Retention Program Guidelines Quorum Review IRB(Quorum) considers recruiting activities to be the beginning of the informed consent process. Consequently, in accordance with its authority to approve or disapprove all research activities,

More information

GCP Refresher and GCP/GCDMP Trends. in the CTN. Denise King, MS, RD, CCRA & Lauren Yesko, BS. Presented by:

GCP Refresher and GCP/GCDMP Trends. in the CTN. Denise King, MS, RD, CCRA & Lauren Yesko, BS. Presented by: GCP Refresher and GCP/GCDMP Trends Presented by: in the CTN Denise King, MS, RD, CCRA & Lauren Yesko, BS CTN WEB SEMINAR SERIES: A FORUM TO EXCHANGE RESEARCH KNOWLEDGE Produced by: CTN Training This training

More information

EVENT TYPE TIMING REQUIRED FORM

EVENT TYPE TIMING REQUIRED FORM Reportable Events EVENT TYPE TIMING REQUIRED FORM Unanticipated Problem or Adverse Event 10 days Event Reporting Form Death (related) 10 days Event Reporting Form Death (not related) Renewal Summary with

More information

Tip Sheet 17: Review of Research by the Expedited Procedure

Tip Sheet 17: Review of Research by the Expedited Procedure Tip Sheet 17: Review of Research by the Expedited Procedure Related Accreditation Elements: II.2.E. Policies and procedures should describe review using the expedited procedure, when an expedited procedure

More information

Embryonic Stem Cell Research Oversight Committee (ESCRO) Application Form

Embryonic Stem Cell Research Oversight Committee (ESCRO) Application Form Embryonic Stem Cell Research Oversight Committee (ESCRO) Application Form A. Demographic Information Date of Submission: Reason for Submission: New Project Response to Comments Reconsideration Disapproval

More information

New NIH Clinical Trial Requirements for Grants & Contracts 2017/2018

New NIH Clinical Trial Requirements for Grants & Contracts 2017/2018 New NIH Clinical Trial Requirements for Grants & Contracts 2017/2018 Changes in Human Subjects Research Grant Application Process Clinical Trial Applications IRB Single IRB Certificates of Confidentiality

More information

Clinical Trials and the Code of Federal Regulations. Darlene Kitterman, MBA Director, Investigator Support & Integration Services September 24, 2014

Clinical Trials and the Code of Federal Regulations. Darlene Kitterman, MBA Director, Investigator Support & Integration Services September 24, 2014 Clinical Trials and the Code of Federal Regulations Darlene Kitterman, MBA Director, Investigator Support & Integration Services September 24, 2014 The Development of Regulations 1906: Food and Drugs Act

More information

Quality Assurance QA STANDARD OPERATING PROCEDURE FOR FDA or Pharmaceutical Sponsored Audits

Quality Assurance QA STANDARD OPERATING PROCEDURE FOR FDA or Pharmaceutical Sponsored Audits Quality Assurance QA 601.01 STANDARD OPERATING PROCEDURE FOR FDA or Pharmaceutical Sponsored Audits Approval: Nancy Paris, MS, FACHE President and CEO 24 May 2017 (Signature and Date) Approval: Frederick

More information

MRCTCenter ExpandedAccess InvestigationalProducts. PracticalApproach Sponsors,Physicians, InstitutionalReview Boards. Boards. Framework Framework

MRCTCenter ExpandedAccess InvestigationalProducts. PracticalApproach Sponsors,Physicians, InstitutionalReview Boards. Boards. Framework Framework MRCT MRCTCenter Center Expanded ExpandedAccess Accesstoto Investigational InvestigationalProducts Products A APractical PracticalApproach Approachfor for Sponsors, Sponsors,Physicians, Physicians, and

More information

Objectives. The Regulatory Binder = Investigator Site File= Trial Center File 8/16/2010. Essential Documents: Maintaining the Site's Regulatory Binder

Objectives. The Regulatory Binder = Investigator Site File= Trial Center File 8/16/2010. Essential Documents: Maintaining the Site's Regulatory Binder Essential Documents: Maintaining the Site's Regulatory Binder How to Manage the Essential Documents for the Investigator and Study Site Objectives Describe the importance of maintaining the Regulatory

More information

Acting Deputy Commissioner for Operations, U.S. Food and Drug Administration

Acting Deputy Commissioner for Operations, U.S. Food and Drug Administration Available on FDA website at: http://www.fda.gov/newsevents/testimony/ucm113266.htm Pediatric Clinical Trials for Anti-depressant Drug Products Statement of Janet Woodcock, M.D. Acting Deputy Commissioner

More information

IRB Considerations for Investigator-Initiated Research

IRB Considerations for Investigator-Initiated Research November 29, 2017 IRB Considerations for Investigator-Initiated Research Robert Romanchuk, BSHS, CIP, CCRC, CCRP IRB Vice Chair, Schulman IRB Introducing advarra.com About Schulman IRB Established in 1983

More information

Regional IRB Consortium Workshop & Meeting Thursday, April 23, 2009 Thomas Foster, Pharm.D., FCCP, FCP, FAPHA

Regional IRB Consortium Workshop & Meeting Thursday, April 23, 2009 Thomas Foster, Pharm.D., FCCP, FCP, FAPHA Regional IRB Consortium Workshop & Meeting Thursday, April 23, 2009 Thomas Foster, Pharm.D., FCCP, FCP, FAPHA Center for Clinical and Translational Science Spring Meeting Lexington Civic Center Hot Topics

More information

Human Research Protection Program Education Plan

Human Research Protection Program Education Plan Human Research Protection Program Education Plan May 1, 2016 Human Research Protections Program e 1313 21 st Ave. South, Room 504 Oxford House, Nashville, Tennessee 37232-4315 e phone 615-322-2918 e fax

More information

Summary of Provisions in 21 st Century Cures Act (H.R. 6) as passed by full House of Representatives, July 10, 2015

Summary of Provisions in 21 st Century Cures Act (H.R. 6) as passed by full House of Representatives, July 10, 2015 Pediatric-Specific Provisions Summary of Provisions in 21 st Century Cures Act (H.R. 6) as passed by full House of Representatives, July 10, 2015 Requires the NIH to complete a strategic plan, and in the

More information

ICH GCP E6(R2): Changes? Yes Challenges? Not as Difficult as You May Fear Lorrie D. Divers, President QRCP Solutions, Inc.

ICH GCP E6(R2): Changes? Yes Challenges? Not as Difficult as You May Fear Lorrie D. Divers, President QRCP Solutions, Inc. ICH GCP E6(R2): Changes? Yes Challenges? Not as Difficult as You May Fear Lorrie D. Divers, President QRCP Solutions, Inc. 25 October 2017: University of Rochester Achieving High Quality Clinical Research

More information

Guidance for Industry and FDA Staff Procedures for Handling Post-Approval Studies Imposed by PMA Order

Guidance for Industry and FDA Staff Procedures for Handling Post-Approval Studies Imposed by PMA Order Guidance for Industry and FDA Staff Procedures for Handling Post-Approval Studies Imposed by PMA Order Document issued on: [Level 2, June 15, 2009] This guidance supersedes the document issued under this

More information

Clinical & Translational Research, What is it and Why Should I Care?

Clinical & Translational Research, What is it and Why Should I Care? Clinical & Translational Research, What is it and Why Should I Care? Ann Smith, Operations Administrative Manager, Clinical & Translational Sciences Institute What is Clinical Research? Research Human

More information

Obtaining Pre-Study Approvals for Clinical Trials K-30 Module 5 Navigating the Pre-Award Process

Obtaining Pre-Study Approvals for Clinical Trials K-30 Module 5 Navigating the Pre-Award Process Obtaining Pre-Study Approvals for Clinical Trials K-30 Module 5 Navigating the Pre-Award Process Helene Orescan, J.D. Bishoy Anastasi, MBA, CCRP David Geffen School of Medicine at UCLA Industry Sponsored

More information

Pre-Screening revised checklist for BA/BE NOC for Export Purpose

Pre-Screening revised checklist for BA/BE NOC for Export Purpose Pre-Screening revised checklist for BA/BE NOC for Export Purpose O/o Drugs Controller General (India) Directorate General of Health Services FDA Bhawan, New Delhi (With effective from 25 th April 2014)

More information

VCU Faculty Held IND and IDE Procedure Handbook

VCU Faculty Held IND and IDE Procedure Handbook VCU Faculty Held IND and IDE Procedure Handbook Contents A. Introduction... 3 B. Purpose of Institutional Oversight... 3 C. Applicability... 4 D. University Oversight of Clinical Investigations Being Conducted

More information

Clinical Research at MSU

Clinical Research at MSU Financial Administration Development Program: Clinical Research at MSU Kristen Burt, Office of Regulatory Affairs (ORA) Sharon Schooley, Clinical & Translational Sciences Institute (CTSI) February 24,

More information

Expedited Reporting. Darlene Kitterman, MBA Director, Investigator Support & Integration Services, OCTRI September 25, 2014

Expedited Reporting. Darlene Kitterman, MBA Director, Investigator Support & Integration Services, OCTRI September 25, 2014 Expedited Reporting Darlene Kitterman, MBA Director, Investigator Support & Integration Services, OCTRI September 25, 2014 Journal of Clinical Research Best Practices Vol. 7, No. 1, January 2011 Can You

More information

DANA-FARBER / HARVARD CANCER CENTER STANDARD OPERATING PROCEDURES FOR HUMAN SUBJECT RESEARCH TITLE

DANA-FARBER / HARVARD CANCER CENTER STANDARD OPERATING PROCEDURES FOR HUMAN SUBJECT RESEARCH TITLE SOP #: DATA-101 Page: 1 of 5 1. POLICY STATEMENT: Case Report Forms (CRFs) are designed by the Clinical Trials Research Informatics Office (CTRIO) in collaboration with the Sponsor, Overall PI, designated

More information

Research Ethics Committee Assessment Toolkit (RECAT) Evaluating the needs of research ethics committees to improve operational quality and efficiency

Research Ethics Committee Assessment Toolkit (RECAT) Evaluating the needs of research ethics committees to improve operational quality and efficiency Research Ethics Committee Assessment Toolkit (RECAT) 2017 Evaluating the needs of research ethics committees to improve operational quality and efficiency The Research Ethics Committee Assessment Toolkit

More information

Managing a Research Team. Mandy Morneault Manager, Research Coordinator Core ITHS Clinical Services

Managing a Research Team. Mandy Morneault Manager, Research Coordinator Core ITHS Clinical Services Managing a Research Team Mandy Morneault Manager, Research Coordinator Core ITHS Clinical Services vicka@uw.edu, 206-355-5210 PI responsibilities and organizing a research team Hiring research staff Effective

More information

Preparing your Audit Response Communication with the Central Office

Preparing your Audit Response Communication with the Central Office Preparing your Audit Response Communication with the Central Office Sally Scherer, Audit Specialist CALGB Central Office CALGB Audit Prep Workshop, June 2006 Preparing Your Audit Response: Communication

More information

Multi-Site Coordination Process. Drafted by: Ester Dimayuga Page 1 of 18

Multi-Site Coordination Process. Drafted by: Ester Dimayuga Page 1 of 18 Multi-Site Coordination Process Drafted by: Ester Dimayuga Page 1 of 18 MULTI-SITE COORDIATIO (MSC) REGULATOR PROCESS CTO-Regulatory notifies MSC of trial with UMCC as coordinating center MSC prepares

More information

Job Title: Biological Science Laboratory Technician (Behavioral Pharmacology), GS $47, to $61, / Per Year

Job Title: Biological Science Laboratory Technician (Behavioral Pharmacology), GS $47, to $61, / Per Year Job Title: Biological Science Laboratory Technician (Behavioral Pharmacology), GS-0404-09 Department: Department Of Health And Human Services Agency: Food and Drug Administration Job Announcement Number:

More information

Australia: A Dynamic Environment for Conducting Clinical Trials

Australia: A Dynamic Environment for Conducting Clinical Trials Australia: A Dynamic Environment for Conducting Clinical Trials MTPConnect s goal is to accelerate the growth of Australia s MTP sector Industry Associations Governments Universities Researchers Investors

More information

IND Exemption, Preparation and Maintenance. Bruce K. Burnett, PhD, RAC (US, EU) Director, Regulatory Affairs Duke University

IND Exemption, Preparation and Maintenance. Bruce K. Burnett, PhD, RAC (US, EU) Director, Regulatory Affairs Duke University IND Exemption, Preparation and Maintenance Bruce K. Burnett, PhD, RAC (US, EU) Director, Regulatory Affairs Duke University 1 Templates and Guidance Best Practices Templates/Instructions http://tiny.cc/d7bpt

More information

How did it evolve? o Public disasters, serious fraud and abuse of human rights. o Trials of War criminals-nuremberg code 1949

How did it evolve? o Public disasters, serious fraud and abuse of human rights. o Trials of War criminals-nuremberg code 1949 ICH GCP Overview What is ICH? ICH is a joint initiative involving both the regulators and the industry as equal partners in the scientific and technical discussions of the testing procedures which are

More information

Preparing for Close-Out of Studies and Sites

Preparing for Close-Out of Studies and Sites Preparing for Close-Out of Studies and Sites Presented by: Christie Thomas, MPH, CCRA Matthew Wright, BS, CCRP Dikla Blumberg, PhD CTN WEB SEMINAR SERIES: A FORUM TO EXCHANGE RESEARCH KNOWLEDGE Produced

More information

Research: Ethics, Informed Consent, FDA, Off Label Use

Research: Ethics, Informed Consent, FDA, Off Label Use Research: Ethics, Informed Consent, FDA, Off Label Use Nasim Hedayati, MD, FACS, RPVI Assistant Professor Division of Vascular and Endovascular Surgery University of California, Davis 2015 Phlebology Review

More information

TOP 10 INVESTIGATOR RESPONSIBILITIES WHEN CONDUCTING HUMAN SUBJECTS RESEARCH

TOP 10 INVESTIGATOR RESPONSIBILITIES WHEN CONDUCTING HUMAN SUBJECTS RESEARCH Investigators Responsibility #1: Design and Implement Ethical Research Consistent with the Three Ethical Principles Delineated in The Belmont Report. The Belmont Report: Three Basic Ethical Principles:

More information

Major Changes to NIH & AHRQ Submissions with Human Subjects

Major Changes to NIH & AHRQ Submissions with Human Subjects Major Changes to NIH & AHRQ Submissions with Human Subjects Good Clinical Practice New Application Forms Single IRB Clinical Trial Review Criteria Get Ready, Get Set, Apply Early. Registration & Reporting

More information

DRUG ORDERING AND MAINTENANCE

DRUG ORDERING AND MAINTENANCE AND MAINTENANCE Disclaimer: Please note that the instructions provided in this chapter mainly apply to agents provided by the Pharmaceutical Management Branch (PMB), of Cancer Therapy Evaluation Program

More information